Next Generation Sequencing Market Set To Grow To Over $5.6bn In 2017

09 August 2017
Pharma

Visiongain has launched a new pharma report The Next Generation Sequencing Market Forecast 2017-2027: Revenue Prospects by Application (Drug Discovery, Genetic Screening, Diagnostics, Personalized Medicine, Agriculture And Animal Research, Infectious Diseases, Others) Technology (Whole-Genome Sequencing, Targeted Re-Sequencing, Exome Sequencing, RNA Seq, Chip Seq, De Novo Sequencing, Methyl Seq, Others), Products (Instruments, Reagents & Consumables, Services), End User (Hospital & Healthcare Institution, Academics, Biotechnology, Pharmaceutical, Others) and Geography

Next-Generation Sequencing (NGS), also known as high-throughput sequencing, can be defined as a process used to sequence DNA strands in parallel and substantially minimize the need for fragment cloning which are used in methods such as Sanger sequencing. NGS is a powerful platform that has enabled the sequencing of millions of DNA molecules whilst simultaneously significantly reducing the cost. With the use of NGS an entire human genome can be sequenced in a day. NGS can be used to sequence entire genomes or constrained to specific areas of interest, including all 22 000 coding genes (a whole exome) or small numbers of individual genes. The data output of NGS has out placed Moore’s Law more than doubling each year.

The development of NGS technologies over the past few years have made large-scale projects such as the Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) feasible. The technique has provided multi-platform data for thousands of tumours from a variety of cancer types and subtypes as well as integrative analyses of genomic, transcriptomic and epigenomic data, thereby increasing our understanding of cancer biology.

The lead Visiongain report analyst for this report commented; “The market for next generation sequencing is mainly driven by factors such as technological advancements in sequencing platforms, increasing applications of next generation sequencing, growing number of partnerships and collaborations, increasing adoption of next generation sequencing technologies among research laboratories and academic institutes. The application of next generation sequencing in a diverse range of medical conditions will provide new growth opportunities to key players in the next generation sequencing market.”

The Next Generation Sequencing market is highly competitive with many different players entering the market. The report discusses selected leading companies in the market. Notable companies in the global next generation sequencing market include Illumina, Inc., Thermo Fisher Scientific Inc., Pacific Biosciences of California, Inc., Qiagen N.V., Beijing Genomics Institute, Perkinelmer, Inc., F. Hoffmann-La Roche AG, Agilent Technologies, Inc., Gatc Biotech AG, Oxford Nanopore Technologies, Ltd., Macrogen, Inc. and Eurofins Scientific.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever